Official websites use. Share sensitive information only on official, secure websites. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Erectile dysfunction ED is a prevalent condition that affects men and their partners. Significant improvements in the sexual lives of these couples have been achieved with the introduction of phosphodiesterase 5 PDE5 inhibitors. Currently, three PDE5 inhibitors β sildenafil, tadalafil and vardenafil β are approved to be taken as needed in anticipation of sexual activity, but only one of these, tadalafil, has been approved to be taken once daily.
Keywords: erectile dysfunction, once-daily treatment, patient and partner perspectives, phosphodiesterase 5 PDE5 inhibitor. Male erectile dysfunction ED is a prevalent condition defined as the persistent inability to obtain and maintain an erection sufficient to permit satisfactory sexual performance.
Use of a medication that inhibits phosphodiesterase type 5 PDE5 is now widely recognized as the first-line therapy for the majority of men with ED.
Many factors can influence patient preference for an ED therapy: drug attributes efficacy, safety, tolerability and pharmacokinetic properties as well as behavioral, psychological and relationship factors.
Although PDE5 inhibitors are easy to use, men must ingest these oral agents on-demand before sexual activity, and thus remain temporally linked to treatment. For some patients and their partners, planning sexual activity around taking a drug is burdensome. Recent study results demonstrated that chronic administration, with tadalafil 8 dosed at 2. Based on patient choice and physician assessment, tadalafil for once-a-day use is for patients who already respond to PDE5-inhibitor therapy and who anticipate sexual activity at least twice weekly.
